delamanid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4819 681492-22-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • deltyba
  • OPC-67683
  • delamanid
an antitubercular agent
  • Molecular weight: 534.49
  • Formula: C25H25F3N4O6
  • CLOGP: 5.61
  • LIPINSKI: 2
  • HAC: 10
  • HDO: 0
  • TPSA: 101.12
  • ALOGS: -5.38
  • ROTB: 9

Drug dosage:

DoseUnitRoute
0.20 g O

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AKT1,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK2,JAK3,MAP2K6,MAP3K1,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 53
kinase-selectivity-class AXL,EIF2AK3,GRK2,PDK4 4
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
July 4, 2014 PMDA
Nov. 22, 2013 EMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Electrocardiogram QT prolonged 220.77 42.44 75 1816 72381 90554175
Anaemia 87.05 42.44 66 1825 352736 90273820
Neuropathy peripheral 82.38 42.44 45 1846 136925 90489631
Vomiting 72.33 42.44 85 1806 788208 89838348
Off label use 62.70 42.44 94 1797 1102158 89524398
Hypokalaemia 47.20 42.44 31 1860 131085 90495471
Incorrect product administration duration 47.08 42.44 17 1874 19305 90607251
Intentional product use issue 45.55 42.44 37 1854 216855 90409701
Meningitis tuberculous 42.97 42.44 8 1883 650 90625906

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Electrocardiogram QT prolonged 350.18 36.00 122 2248 47823 42571142
Neuropathy peripheral 128.07 36.00 76 2294 101777 42517188
Incorrect product administration duration 88.24 36.00 26 2344 5854 42613111
Tuberculosis 86.12 36.00 29 2341 10070 42608895
Anaemia 79.28 36.00 87 2283 280191 42338774
Intentional product use issue 78.27 36.00 49 2321 71784 42547181
Vomiting 63.57 36.00 79 2291 289644 42329321
Off label use 59.49 36.00 117 2253 638218 41980747
HIV infection 38.07 36.00 10 2360 1475 42617490
Deafness neurosensory 36.88 36.00 12 2358 3734 42615231
Drug resistance 36.30 36.00 23 2347 34225 42584740

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Electrocardiogram QT prolonged 545.49 31.92 192 4179 108768 110476160
Neuropathy peripheral 228.09 31.92 120 4251 179157 110405771
Anaemia 156.25 31.92 146 4225 546940 110037988
Incorrect product administration duration 128.80 31.92 43 4328 20455 110564473
Vomiting 113.45 31.92 158 4213 910517 109674411
Off label use 111.09 31.92 205 4166 1499980 109084948
Intentional product use issue 104.76 31.92 83 4288 247823 110337105
Tuberculosis 83.43 31.92 30 4341 17744 110567184
Drug resistance 63.75 31.92 35 4336 56339 110528589
Psychotic disorder 61.42 31.92 33 4338 50904 110534024
Optic neuritis 56.79 31.92 20 4351 11127 110573801
Hypokalaemia 56.20 31.92 51 4320 182397 110402531
Drug-induced liver injury 54.48 31.92 42 4329 120025 110464903
Aspartate aminotransferase increased 49.82 31.92 45 4326 159891 110425037
Meningitis tuberculous 48.28 31.92 11 4360 1267 110583661
HIV infection 48.07 31.92 11 4360 1292 110583636
Haemoglobin decreased 42.99 31.92 51 4320 248676 110336252
Respiratory failure 40.29 31.92 46 4325 215286 110369642
Blood sodium decreased 38.43 31.92 22 4349 38297 110546631
Gastroenteritis 38.18 31.92 22 4349 38778 110546150
Polyneuropathy 36.52 31.92 20 4351 31992 110552936
Benign soft tissue neoplasm 36.07 31.92 6 4365 131 110584797
Product use in unapproved indication 34.97 31.92 63 4308 447314 110137614
Pneumothorax 34.70 31.92 20 4351 35265 110549663
Bicytopenia 34.00 31.92 12 4359 6712 110578216
Drug ineffective 32.46 31.92 10 4361 1520530 109064398

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J04AK06 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Other drugs for treatment of tuberculosis
CHEBI has role CHEBI:33231 antitubercular agent

Related Drugs by ATC class:

J04AK Other drugs for treatment of tuberculosis 7 drugs
bedaquilineethambutolmorinamidepretomanidpyrazinamideterizidonethioacetazone

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Drug resistant tuberculosis indication 423709000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.92 Basic
pKa2 4.66 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D09785 KEGG_DRUG
CHEBI:134742 CHEBI
CHEMBL218650 ChEMBL_ID
C516022 MESH_SUPPLEMENTAL_RECORD_UI
12876 IUPHAR_LIGAND_ID
DB11637 DRUGBANK_ID
8OOT6M1PC7 UNII
015849 NDDF
714097004 SNOMEDCT_US
714098009 SNOMEDCT_US
C3489682 UMLSCUI
9401 INN_ID
6480466 PUBCHEM_CID

Pharmaceutical products:

None